Indevus Bulks Up Marketing Muscle
Indevus Pharmaceuticals (IDEV) has picked up a stronger marketing partner for its overactive bladder drug Sanctura XR.
The centerpiece of the acquisition is the U.S. marketing rights to Sanctura XR, which Indevus had previously licensed to Esprit.
Sanctura XR has the potential to be the best-in-class drug to treat overactive bladder -- a $2 billion drug market. The challenge is marketing. So-called OAB drugs require a lot of it, something that Indevus and Esprit couldn't handle on their own, especially when the big competition comes from drugs sold by Big Pharma giants like GlaxoSmithKline (GSK) and Pfizer (PFE).Allergan, however, is an experienced drug marketer, especially in eye care and dermatology. Selling genitourinary drugs like Sanctura XR is a new business for Allergan, but its sales expertise is likely what the drug needs to make a significant dent in the OAB market. This optimism for Sanctura XR -- and therefore for Indevus -- don't seem to be on display in the company's stock price, however. Indevus shares were off 19 cents, or 2.6%, to $7.09 in recent trading, even as Allergan shares were up 81 cents, or 1%, to $63.03. That's a bit hard to understand. If paying $370 million to gain control of U.S. rights to Sanctura XR is good for Allergan, logic suggests that the deal should also be good for Indevus, which will receive sales royalties from Allergan based on Sanctura XR revenue.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV